Vuno Inc. engages in the artificial intelligence medical software development and services business. The company provides medical AI solutions for analyzing various medical data and assisting in disease diagnosis. It also offers BoneAge, an AI diagnostic software for bone age assessment; DeepBrain, a brain parcellation for the quantitative analysis of neurodegenerative diseases and other neurological disorders; chest X-ray, a diagnostic support system for abnormalities in chest x-ray; fundus AI, an AI-based screening solution for various abnormalities in the fundus of the eye; DeepCARS, an AI-based cardiac arrest risk management system; and LungCT AI, an AI-based pulmonary lung nodule detection and reporting system. In addition, the company provides medical products under HATIV brand, such as HATIV K30, a kiosk-type medical device that measures electrocardiograms; HATIV P30, a medical ECG device; HATIV BP30, an automatic blood pressure monitoring device; and HATIV TP50T, an ear infrared thermometer device. The company was founded in 2014 and is headquartered in Seoul, South Korea.
Frequently asked questions
What sector does Vuno Inc. (338220) operate in?
Vuno Inc. belongs to the Energy sector and operates in the Health Information Services industry.
What is Vuno Inc. (338220) current stock price?
As of the latest data, Vuno Inc. stock price is ₩7,910, with a previous close of ₩7,910.
What is Vuno Inc. (338220) current market capitalization?
Vuno Inc. market cap is approximately 110.75 billion.
Does Vuno Inc. (338220) pay dividends?
No. Vuno Inc. does not pay a dividend.
What is Vuno Inc. (338220) beta (volatility) score?
Vuno Inc. has a beta of 1.026, meaning its volatility is roughly in line with the market.
